Quarterly ResultJul 28, 2026, 04:13 PM
NeoGenomics Q2 Net Income $2.24M, EPS $0.02; Revenue Up 11.2%
AI Summary
NeoGenomics reported a significant financial turnaround for Q2 2026, achieving a net income of $2.24 million, or $0.02 per share, compared to a substantial loss in the prior year. Revenue increased by 11.2% to $201.66 million. The company also completed a debt refinancing, issuing $316.3 million in new convertible senior notes and repaying $262.89 million of existing notes, resulting in an $11.18 million gain on debt extinguishment.
Key Highlights
- Q2 2026 net income was $2.24 million, up from a net loss of $45.09 million in Q2 2025.
- Q2 2026 basic EPS was $0.02, compared to $(0.35) in Q2 2025.
- Q2 2026 net revenue increased 11.2% to $201.66 million from $181.33 million YoY.
- Issued $316.3 million in 0.75% Convertible Senior Notes due 2032.
- Repaid $262.89 million of 0.25% Convertible Senior Notes due 2028.
- Recognized an $11.18 million gain on extinguishment of debt.
- Net cash provided by operating activities was $11.82 million for H1 2026.
- Repurchased $25.00 million of common stock in H1 2026.
Price Impact
More from NEO